文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

外周灌注导向复苏对血管扩张性休克死亡率的影响:随机试验的系统评价与双重频率学派-贝叶斯Meta分析

Mortality Effect of Peripheral Perfusion-Guided Resuscitation in Vasodilatory Shock: A Systematic Review and Dual Frequentist-Bayesian Meta-Analysis of Randomized Trials.
PubMed 文献 · Crit Care Med · 2026-09-11
一句话结论在脓毒症休克成人中,外周灌注导向复苏的28天死亡率RR为0.87(95%CI 0.76-1.01),频率学派分析未达统计学显著,贝叶斯分析估计RR<1的后验概率为97.2%。

该系统评价与双重Meta分析检索了PubMed、Embase、Cochrane CENTRAL和Scopus(建库至2025年11月),纳入7项RCT共2408例脓毒症休克成人,比较外周灌注导向复苏与标准治疗或乳酸导向复苏。主要频率学派随机效应模型显示28天死亡率RR 0.87(95%CI 0.76-1.01;p=0.06;中等 certainty 证据),置信区间跨过无效线,未检出异质性(I2=0%)。预设的贝叶斯分析估计RR<1的后验概率为97.2%,在不同先验假设下大致一致。作者认为该信号的方向一致但效应量仍不确定,需要足够把握度的试验确认其是否具有临床意义。

要点

  • 在脓毒症休克成人中,外周灌注导向复苏的28天死亡率频率学派合并RR为0.87(95%CI 0.76-1.01;p=0.06),未达统计学显著。
  • 两项最大且偏倚风险最低的试验各自均无统计学显著结果。
  • 贝叶斯分析估计RR<1的后验概率为97.2%,在不同先验假设下大致一致,方向与频率学派结果一致。
  • 合并分析未检出异质性(I2=0%),证据确定性为中等。
  • 作者认为效应量仍不确定,需要足够把握度的试验确认该信号是否反映临床有意义的获益。

适用人群与场景

  • 所有纳入试验均入组脓毒症休克成人患者。

处置流程与药物剂量

  • 干预为外周灌注导向复苏,对照为标准治疗或乳酸导向复苏。

研究设计与关键结果

  • 研究类型为系统评价与双重频率学派-贝叶斯Meta分析,纳入7项RCT共2408例脓毒症休克成人,比较外周灌注导向复苏与标准治疗或乳酸导向复苏。
  • 主要频率学派随机效应模型:28天死亡率合并RR 0.87(95%CI 0.76-1.01;p=0.06;中等确定性证据),置信区间跨过无效线,未检出异质性(I2=0%)。
  • 两项最大且偏倚风险最低的试验各自均无统计学显著结果。
  • 预设贝叶斯分析估计RR<1的后验概率为97.2%,在不同先验假设下大致一致。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析,采用Cochrane RoB 2.0评估偏倚风险、GRADE评估证据确定性,频率学派分析为中等确定性证据。
  • 局限:两项最大且偏倚风险最低的试验各自均无统计学显著结果;频率学派合并结果的置信区间跨过无效线;作者指出效应量仍不确定,需要足够把握度的试验确认。

对床旁实践的改变

  • 作者认为外周灌注导向复苏在脓毒症休克成人中呈现28天死亡率降低的信号,但频率学派分析未达统计学显著,效应量仍不确定,需要足够把握度的试验确认其是否具有临床意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the effect of peripheral perfusion-guided resuscitation on 28-day mortality in adults with vasodilatory shock.

DATA SOURCES: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and Scopus from inception to November 2025.

STUDY SELECTION: We included randomized controlled trials (RCTs) comparing peripheral perfusion-guided resuscitation with standard care or lactate-guided resuscitation; all eligible trials enrolled patients with septic shock.

DATA EXTRACTION: Trial characteristics, intervention and comparator protocols, and outcomes were extracted. Risk of bias was assessed with the Cochrane Risk of Bias tool for randomized trials 2.0 tool and certainty of evidence with the Grading of Recommendations, Assessment, Development, and Evaluation approach. We conducted a prespecified dual-framework meta-analysis comprising a primary frequentist random-effects model and a Bayesian hierarchical model with alternative prior assumptions. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and was preregistered with PROSPERO (CRD420251229564).

DATA SYNTHESIS: Seven RCTs (n = 2408) were included. In the primary frequentist analysis, the pooled risk ratio (RR) for 28-day mortality with peripheral perfusion-guided resuscitation was 0.87 (95% CI, 0.76-1.01; p = 0.06; moderate-certainty evidence), with the CI crossing the line of no effect. No heterogeneity was detected (I2 = 0%). The two largest and lowest-risk trials were individually nonsignificant. The prespecified Bayesian analysis estimated a 97.2% posterior probability that RR is less than 1 (P [RR < 1]), broadly consistent across alternative prior assumptions.

CONCLUSIONS: Among adults with septic shock, peripheral perfusion-guided resuscitation yielded a lower 28-day mortality estimate that did not meet statistical significance in the frequentist analysis. The Bayesian component of the dual framework was directionally concordant, estimating a high posterior probability that RR is less than 1, although the magnitude of any effect remains uncertain. Adequately powered trials are needed to confirm whether this signal reflects a clinically meaningful benefit.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mendes H, Silva Correia JV, Moreira Salles MM, et al. Mortality Effect of Peripheral Perfusion-Guided Resuscitation in Vasodilatory Shock: A Systematic Review and Dual Frequentist-Bayesian Meta-Analysis of Randomized Trials. Crit Care Med. 2026. PMID: 42725818. doi:10.1097/CCM.0000000000007364

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。